Table 4. Ongoing clinical trials in head and neck cancer with selective PI3K inhibitors.
| Compound | Combination | Phase | State | NCT number |
|---|---|---|---|---|
| Alpelisib | Cisplatin + IMRT | 1 | Recruiting | NCT02537223 |
| Paclitaxel | 1 | Completed | NCT02051751 | |
| Cetuximab + IMRT | 1 | Recruiting | NCT02282371 | |
| Cetuximab | 1b | Terminated | NCT01602315 | |
| / | 2 | Not yet recruiting | NCT02145312 | |
| Cetuximab + Cisplatin | 1/2 | Not yet recruiting | NCT02298595 | |
| AMG319 | / | 2 | Recruiting | NCT02540928 |
IMRT: Intensity-modulated radiation therapy, NCT: Number clinicaltrials.gov identifier.